Compare BNTX & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNTX | RVMD |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Germany | United States |
| Employees | N/A | 883 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 19.2B |
| IPO Year | 2019 | N/A |
| Metric | BNTX | RVMD |
|---|---|---|
| Price | $111.58 | $148.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | $133.46 | ★ $139.58 |
| AVG Volume (30 Days) | 711.3K | ★ 3.2M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.37 | $533.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $79.81 | $34.00 |
| 52 Week High | $124.00 | $155.70 |
| Indicator | BNTX | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 75.58 | 79.69 |
| Support Level | $106.52 | $93.39 |
| Resistance Level | $113.02 | N/A |
| Average True Range (ATR) | 3.17 | 5.76 |
| MACD | 2.45 | 5.07 |
| Stochastic Oscillator | 95.94 | 88.72 |
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.